In the topsy-turvy world of 2026, where the “Defense Production Act” is apparently the go-to tool for propping up 19th-century fuel sources and the Lincoln Memorial is getting a fancy new promenade, the stock market has decided to play a game of “Good News is Actually Terrifying.” On Friday, June 5, the U.S. economy added a staggering 172,000 jobs\u2014more than double the 80,000 that boring economists had predicted. Naturally, Wall Street reacted with the grace of a startled cat in a room full of rocking chairs.<\/p>\n
The S&P 500<\/a> (-1.60%) tumbled to 7,463.24, while the tech-heavy NASDAQ<\/a> (-2.65%) took a 26,122.36-point nose dive. Even the Dow Jones Industrial Average<\/a> (-0.74%), which usually enjoys a good old-fashioned jobs boost, slipped to 51,182.31. The reason? Investors are deathly afraid that if Americans keep having the audacity to be employed, the Federal Reserve might actually raise interest rates in December. It\u2019s a classic case of “the economy is too healthy, so we must punish the stocks.”<\/p>\n President Donald Trump, ever the observant market commentator, took to Truth Social<\/b> to express his profound bewilderment. “Stocks should go up, not down,”<\/i> he posted, seemingly puzzled that the “massive jobs boost” he helped create resulted in a sea of red on his Bloomberg terminal. It\u2019s almost as if the market\u2019s relationship with reality has been replaced by a complex algorithm that views human prosperity as a precursor to a rate-hike-induced apocalypse.<\/p>\n While the broader market was busy panic-selling, the administration decided to double down on its “Beautiful, Clean Coal” initiative. Invoking the Defense Production Act<\/b>\u2014a power usually reserved for things like, you know, national emergencies or wars\u2014Trump announced a $700 million plan to boost the coal industry. The package includes $425 million to upgrade 13 existing coal-fired power plants and $75 million for a new export terminal in Oakland, California. Because if there\u2019s one thing Oakland is known for, it\u2019s its burning desire to be a hub for 1800s energy exports.<\/p>\n The immediate reaction in the coal sector was a brief, euphoric spike. On Thursday, BTU<\/a> (+4.0%)\u2014Peabody Energy\u2014and HNRG<\/a> (+4.47%)\u2014Hallador Energy\u2014were the darlings of the trading floor. However, the Friday “jobs-are-bad” sell-off eventually caught up with them. By midday Friday, BTU<\/a> (-7.63%) had surrendered all its gains and then some, trading around $31.22. It turns out that even the Defense Production Act can\u2019t defend a stock price against a 70% probability of a Fed rate hike.<\/p>\n Analysts at UBS<\/b> recently lowered their price target for BTU<\/a> to $32, maintaining a “Neutral” rating. It seems the “structural policy tailwinds” of reduced royalty rates and tax credits are being weighed against the minor detail that the rest of the world is still trying to figure out how to breathe. But hey, at least 14,000 jobs are “protected,” even if the stock price is currently unprotected from gravity.<\/p>\n If you thought the coal announcement was bold, wait until you hear about the plan for your medicine cabinet. Trump has renewed his threat to impose pharmaceutical tariffs that could eventually reach a staggering 250%. “We want pharmaceuticals made in our country,”<\/i> he told CNBC, with the casual tone of someone suggesting we order pizza. The plan is to start with “small” tariffs and ramp them up to 150% and then 250% over the next 18 months.<\/p>\n The market reaction has been a mixture of frantic capital investment and quiet weeping from healthcare CFOs. LLY<\/a> (+0.05%)\u2014Eli Lilly\u2014has already pledged $50 billion to U.S. manufacturing to get ahead of the “Tariff Bombshell.” Meanwhile, foreign giants like Novartis<\/b> and Roche<\/b> are staring down potential annual losses in the hundreds of millions. The S&P 500 Health Care Sector<\/a> (-1.1%) is currently having its worst year relative to the broader market in 25 years, down nearly 12% year-over-year.<\/p>\n The logic is simple: tax the life-saving drugs until they are made in Ohio. The potential side effect? Skyrocketing prescription costs for millions of Americans. But as the administration frames it, this is a “win for small businesses” and a blow to the “Green New Scam.” It\u2019s a bold strategy to lower the cost of living by making everything imported cost three times as much, but who are we to question the “single largest deregulatory action in American history”?<\/p>\n Amidst the threats to the UK over “forced labor” and the 60 other trade partners currently in the crosshairs, there is one bright spot: India. Trump has shown renewed confidence in a long-anticipated U.S.-India trade deal, aiming for a $500 billion trade target by 2030. Investors looking to play this potential bromance have been piling into the EPI<\/a> (+0.05%)\u2014WisdomTree India Earnings Fund\u2014which weights its holdings by earnings rather than market cap. It\u2019s a refreshing change of pace\u2014a trade policy that involves actually trading things rather than just threatening to tax them into oblivion.<\/p>\n And let\u2019s not forget the “Promenade.” In a move that surely has the DOW<\/b>‘s industrial components salivating, Trump announced a plan to build a promenade connecting the Lincoln Memorial to the Potomac. While the price tag for this architectural flourish wasn’t immediately clear, the Senate Republicans did manage to pass a $70 billion immigration bill this week, proving that there is always money in the banana stand\u2014or, in this case, the federal budget\u2014for large-scale projects.<\/p>\nCoal: Because Nothing Says ‘Defense’ Like Carbon<\/h2>\n
The 250% Solution: Pharmaceutical Tariffs and Reshoring<\/h2>\n
Trade Deals, Promenades, and the India Connection<\/h2>\n
Conclusion: The Volatility is the Policy<\/h2>\n